Touchlight Highlights Data Indicating Higher Lentiviral Vector Yields With dbDNA Platform

According to a recent LinkedIn post from Touchlight, new data suggests that its dbDNA platform, when used with the FuGENE 4K transfection reagent, may deliver substantially higher lentiviral vector production than traditional plasmid DNA. The post references a comparative study in 3rd‑generation LVV systems using HEK293T cells.

The company’s LinkedIn post highlights reported gains of up to three times higher infectious titres in adherent cultures and a twofold increase while using 50% less DNA and reagent, which could support improved cost of goods for LVV manufacturing. It also cites 2.4 times higher titres in a scalable suspension LVV production process, a point that may interest investors tracking cost-efficient cell and gene therapy supply chains.

For investors, the post suggests potential competitive differentiation for Touchlight in the viral vector and advanced therapies manufacturing ecosystem, where cost and scalability are critical constraints. If these performance and efficiency gains are validated and adopted by partners or customers, they could translate into stronger commercial traction for dbDNA-based solutions and reinforce the company’s positioning in the gene therapy tools market.